SGHT Sight Sciences Inc.

Sight Sciences Inc.

Medical/Dental Instruments

Health Care

Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

IPO Year: 2021

Exchange: NASDAQ

Website: sightsciences.com

Recent Analyst Ratings for Sight Sciences Inc.

Date	Price Target	Rating	Analyst
12/6/2024	$5.50	Buy	UBS
11/4/2024	$10.00 → $5.00	Buy → Hold	Lake Street
8/21/2024	$10.00	Buy	Lake Street
9/12/2023	$10.00 → $4.50	Neutral → Underperform	BofA Securities
9/12/2023	$15.00 → $5.50	Overweight → Neutral	Piper Sandler
9/12/2023		Outperform → Mkt Perform	William Blair
8/24/2023	$12.00 → $8.40	Overweight → Equal-Weight	Morgan Stanley
7/10/2023	$15.00 → $9.00	Buy → Neutral	Citigroup
1/6/2023	$10.00 → $15.00	Hold → Buy	Stifel
10/4/2022		Hold	Needham

See more ratings

Sight Sciences Inc.

Recent Analyst Ratings for Sight Sciences Inc.

Sight Sciences Inc. SEC Filings

SEC Form 8-K filed by Sight Sciences Inc.

SEC Form SD filed by Sight Sciences Inc.

SEC Form 10-Q filed by Sight Sciences Inc.

Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Sight Sciences Inc.

SEC Form DEF 14A filed by Sight Sciences Inc.

Sight Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-K filed by Sight Sciences Inc.

Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Sight Sciences Inc. filed SEC Form 8-K: Leadership Update

Sight Sciences Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Mazzacco Catherine was granted 30,952 shares, increasing direct ownership by 65% to 78,507 units (SEC Form 4)

Director Larsen-Becker Brenda Jane was granted 30,952 shares, increasing direct ownership by 64% to 79,040 units (SEC Form 4)

Director Rogers Erica J. was granted 30,952 shares, increasing direct ownership by 21% to 175,352 units (SEC Form 4)

Director Fountain Tamara was granted 30,952 shares, increasing direct ownership by 61% to 81,389 units (SEC Form 4)

Director Zurbay Donald was granted 30,952 shares, increasing direct ownership by 23% to 165,352 units (SEC Form 4)

Director Encrantz Staffan bought $381,958 worth of shares (90,525 units at $4.22) and was granted 30,952 shares, increasing direct ownership by 10% to 1,377,964 units (SEC Form 4)

Director Encrantz Staffan bought $376,429 worth of shares (98,782 units at $3.81), increasing direct ownership by 9% to 1,256,487 units (SEC Form 4)

Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

EVP, Research & Development Raheja Manohar K. was granted 12,767 shares, increasing direct ownership by 8% to 167,767 units (SEC Form 4)

Chief Financial Officer Bauerlein Alison sold $45,430 worth of shares (13,066 units at $3.48), decreasing direct ownership by 2% to 636,728 units (SEC Form 4)